Official figures put NHS uptake of Palantir’s Cancer 360 app at just five or six trusts, while Freedom of Information responses show discrepancies between claimed benefits and recorded use. The gap matters as the government considers the future of the £330 million data platform contract, The Register reports.
Watch Desk analysis
What happened
Cancer 360 was designed to bring cancer patient information from spreadsheets and electronic health records into one system, helping health professionals prioritise treatment. The Register says pilots began four years ago, but official figures put use at five or six NHS trusts. Figures published in October said six trusts were using the app and five benefiting, without naming them or explaining the increase.
The records do not all line up. NHS England told a Freedom of Information requester that six trusts had reported unique users logging into the app over the previous 12 months. Chelsea and Westminster Hospital and Royal United Hospitals Bath, both previously cited as successful pilots, were listed as having zero unique users in that period. East Lancashire Hospitals reported one user, then said in a later FOI response that it was not live with the platform.
Other trusts gave different reasons for not adopting the app: East Kent said it had no immediate requirement, while Bedfordshire cited issues with metadata requirements. NHS England’s figures have since been removed from its website, according to The Register.
The article also puts a frequently cited benefit in context. NHS England previously said Chelsea and Westminster’s share of patients diagnosed within 28 days rose from 72 per cent to 85 per cent during a pilot. But national cancer waiting-time figures have improved more broadly, and the article says those gains cannot simply be credited to Cancer 360 given its limited uptake.
Why it matters
A public-sector software platform can sound transformative in a contract announcement and still have a small or uneven footprint in practice. Here, the mismatch between reported benefits, trust-level adoption and login figures makes it harder to judge what the app has achieved, and for whom.
That scrutiny has a live consequence: the government is deciding whether to continue the Palantir-led contract beyond February 2027. The Register says reports this week suggest renewal is likely, alongside a parallel procurement for an alternative. Those are reported plans, not a concluded procurement decision.
Our read
The useful question is not whether Cancer 360 is a success or failure in the abstract. It is whether the NHS can show, trust by trust, who is using it and what measurable improvement follows. If the records cannot answer that cleanly, a contract renewal should come with clearer evidence than a polished case study and a handful of login counts.
What to watch
- Whether NHS England explains the differing figures and identifies which trusts are actively using Cancer 360.
- What evidence supports claims about faster diagnosis and other patient benefits.
- Whether the government confirms a renewal, launches a parallel procurement, or does both.
Discussion spark: Should the NHS renew a major data-platform contract before it can clearly show which trusts use a key app and what patient benefit it delivers?
Sources and evidence
- Palantir's NHS cancer app gets plenty of praise, precious few users – The Register (13 November 2026, 09:30 UTC)
Watch Desk is operated by WittyWires as an independent cross-cutting AI news tracker. It does not speak for the organisations or people it covers.